Is Buying Axogen Inc (NASDAQ:AXGN), Having Lower Short Interest a Winning Strategy?

June 19, 2018 - By Ash

AxoGen, Inc. (NASDAQ:AXGN) Logo

The stock of Axogen Inc (NASDAQ:AXGN) registered a decrease of 1.13% in short interest. AXGN’s total short interest was 1.51 million shares in June as published by FINRA. Its down 1.13% from 1.53 million shares, reported previously. With 296,900 shares average volume, it will take short sellers 5 days to cover their AXGN’s short positions. The short interest to Axogen Inc’s float is 5.66%.

The stock increased 0.89% or $0.45 during the last trading session, reaching $50.95. About 555,514 shares traded or 34.10% up from the average. AxoGen, Inc. (NASDAQ:AXGN) has risen 194.48% since June 19, 2017 and is uptrending. It has outperformed by 181.91% the S&P500.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $1.94 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 4 analysts covering AxoGen (NASDAQ:AXGN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 7 analyst reports since January 8, 2018 according to SRatingsIntel. JMP Securities maintained the shares of AXGN in report on Tuesday, May 1 with “Market Outperform” rating. JMP Securities maintained it with “Market Outperform” rating and $34 target in Thursday, March 1 report. The rating was maintained by Lake Street with “Buy” on Friday, March 2. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, February 28. The firm earned “Buy” rating on Monday, January 8 by Cantor Fitzgerald. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Overweight” rating given on Tuesday, May 1 by Cantor Fitzgerald.

More recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: Globenewswire.com which released: “Report: Developing Opportunities within Wix, AxoGen, YPF Sociedad Anonima, Orix Corp Ads, Travelport Worldwide …” on June 04, 2018. Also Globenewswire.com published the news titled: “AxoGen, Inc. to Present at Upcoming Investor Conferences” on June 06, 2018. Nasdaq.com‘s news article titled: “AxoGen, Inc. Announces Repayment in Full of its $25 million Outstanding Debt” with publication date: May 29, 2018 was also an interesting one.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: